Spirochaetes Bacteria and the Ixodes Tick: Lyme Disease in a Warming World

Abstract

Lyme disease, caused by the spirochetal bacterium Borrelia burgdorferi sensu lato and transmitted by Ixodes ticks, represents one of the most significant vector-borne public health challenges in the Northern Hemisphere. This report provides an exhaustive synthesis of the current state of Lyme borreliosis as of 2025. We explore the deep evolutionary history of the pathogen, which predates human settlement in North America by millennia, and contrast its genomic stability with the rapid ecological changes driving its current expansion. We examine the molecular mechanisms of pathogenesis, specifically the reciprocal regulation of outer surface proteins that facilitates host evasion. Furthermore, we analyze the profound impact of anthropogenic climate change on vector phenology and range expansion, particularly into Canada and the western United States. Finally, we review the shifting paradigm of chronic illness management following the 2025 National Academies consensus report on Lyme Infection-Associated Chronic Illnesses (Lyme IACI) and evaluate the frontier of therapeutic interventions, including the VLA15 vaccine and selective antimicrobials like Hygromycin A.

I. Introduction: The Silent Epidemic Re-Emerges

In the mid-1970s, a cluster of juvenile arthritis cases in Lyme, Connecticut, brought a "new" disease to the attention of the medical community. Yet, the biological entity responsible for this outbreak, Borrelia burgdorferi, was anything but new. It is an ancient organism that has co-evolved with its arachnid vectors and vertebrate hosts for eons, surviving in ecological refugia through ice ages and interglacial periods.¹ The emergence of Lyme disease in the late 20th century was not the result of a sudden bacterial mutation, but rather the consequence of dramatic landscape modifications—reforestation, suburbanization, and the fragmentation of diverse ecosystems—that brought humans into intimate contact with the enzootic cycle of the spirochete.²

As we stand in 2025, Lyme disease is the most prevalent vector-borne disease in the United States and Europe. The Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 Americans are diagnosed and treated for Lyme disease annually.³ This figure, derived from insurance claims and clinical data, likely captures both confirmed infections and empiric treatments, reflecting the complexities of diagnosis in a landscape where surveillance definitions have recently shifted.³ The disease is no longer confined to the wooded enclaves of New England; it is a continental problem, expanding northward into the Canadian provinces at a rate of tens of kilometers per year, and manifesting in new hotspots in the Midwest and Appalachia.⁵

The causative agent, Borrelia burgdorferi, is a master of evasion. It is an obligate parasite with a segmented genome that is unique among bacteria, allowing it to navigate the distinct environments of the tick midgut and the mammalian bloodstream.⁸ Its ability to persist in the host despite an active immune response has fueled decades of medical controversy regarding chronic symptoms. However, the release of the 2025 National Academies of Sciences, Engineering, and Medicine (NASEM) consensus report has fundamentally altered this landscape, validating the experiences of patients with Lyme Infection-Associated Chronic Illness (Lyme IACI) and pivoting the scientific focus toward finding biological mechanisms and effective treatments.⁹

This report aims to provide a definitive reference on Lyme disease. It weaves together the disparate threads of genomics, ecology, immunology, and climatology to present a holistic view of a pathogen that is uniquely adapted to the Anthropocene.

II. Evolutionary Origins and Phylogeography

To understand the present-day epidemiology of Lyme disease, one must look back into deep time. The genetic structure of Borrelia burgdorferi populations in North America tells a story of ancient colonization, isolation, and recent re-expansion.

The Antiquity of Borrelia burgdorferi

Contrary to the popular narrative of a "new" plague, genomic analyses utilizing multilocus sequence typing (MLST) have revealed that B. burgdorferi has been present in North America for a vast period, potentially millions of years.¹⁰ The genetic diversity observed in modern Borrelia populations is extensive and ancient, predating the Last Glacial Maximum (~20,000 years ago) and certainly the Lyme epidemic of the last 40 years.¹¹

Phylogeographic reconstruction suggests that during the Pleistocene epoch, as ice sheets covered much of the continent, B. burgdorferi populations retreated into refugia—areas where the climate remained hospitable for ticks and their hosts. Genetic evidence points to at least two distinct relict foci: one likely in the Northeast and another in the Midwest.¹ These populations were isolated for thousands of years, accumulating distinct genetic signatures.

As the glaciers retreated and the climate warmed, these ancient populations expanded. The "emergence" of Lyme disease in the 20th century is, in evolutionary terms, a "re-emergence" or a demographic explosion of these ancient lineages. The rapid reforestation of the northeastern United States following the decline of agriculture in the 19th and 20th centuries essentially rebuilt the ancient habitat of the spirochete, allowing the tick vectors to reconnect these bacterial populations with a new, abundant host: humans.¹

Genomic Architecture: Stability and Plasticity

The genome of B. burgdorferi is a biological anomaly. Unlike most bacteria that possess a single circular chromosome, B. burgdorferi carries a linear chromosome and a large, complex collection of linear and circular plasmids (up to 21 in some strains).¹³ This multipartite genome is critical to its survival strategy.

• The Chromosome: The main linear chromosome is remarkably stable and conserved across different strains and species. It encodes the housekeeping genes essential for replication and basic metabolism. The rate of recombination in the chromosome is low, preserving the core genetic identity of the species over millennia.¹⁴

• The Plasmids: In stark contrast, the plasmids are dynamic and plastic. They carry the genes encoding the outer surface proteins (Osps) and other virulence factors required for infection and immune evasion. These plasmids are hotspots for recombination, allowing the bacteria to rapidly shuffle their surface antigens.¹³

This genomic division of labor allows B. burgdorferi to maintain a stable metabolic core while presenting a constantly shifting face to the host immune system. The gene ospC, located on the circular plasmid cp26, is a prime example. It exhibits high sequence variation due to diversifying selection driven by the host's immune response. This variation is not random; it is functionally constrained to maintain the protein's essential role in establishing early infection while evading antibody recognition.¹⁴

Comparative Evolution: The Tale of Two Spirochetes

A compelling insight into Borrelia evolution comes from comparing B. burgdorferi (tick-borne) with Borrelia recurrentis (louse-borne). B. recurrentis, the agent of louse-borne relapsing fever, is a genomic "wreck." Analysis of ancient DNA indicates that B. recurrentis emerged very recently—likely within the last 2,000 to 6,000 years—as a clone of Borrelia duttonii that jumped from ticks to human body lice.¹⁵

This host switch was accompanied by massive "reductive evolution." B. recurrentis has lost a significant portion of its genome and accumulated numerous pseudogenes (broken genes).¹⁵ This rapid decay reflects its specialization to a restricted niche (the human louse) where many genes needed for survival in the environment or diverse hosts were no longer necessary.

In contrast, B. burgdorferi has retained a large, complex genome over millions of years. This stability reflects its ecological niche as a generalist. It must survive in the Ixodes tick (which spends 98% of its life in the soil/leaf litter) and infect a broad range of vertebrate hosts (mice, birds, chipmunks). This requires a versatile genetic toolkit that cannot be discarded. Thus, while B. recurrentis is a specialized evolutionary sprinter that rapidly degraded, B. burgdorferi is an evolutionary marathon runner, maintaining a complex genome to master a complex environment.¹⁵

Table 1: Comparative Evolutionary Genomics of Borrelia Species

Feature	Borrelia burgdorferi (Lyme Agent)	Borrelia recurrentis (Relapsing Fever Agent)
Vector	Hard Ticks (Ixodes spp.)	Human Body Louse (Pediculus humanus humanus)
Evolutionary Age	Ancient (Millions of years) 10	Recent (~2,000 - 6,000 years) 15
Genome Stability	High stability; complex plasmid system	Rapid reductive evolution; gene loss & pseudogenes
Ecological Niche	Generalist (Multiple hosts/environment)	Specialist (Restricted to human/louse cycle)
Virulence	Chronic, persistent infection	Acute, high-mortality epidemic potential

III. The Enzootic Cycle and Vector Ecology

Lyme disease is not passed from person to person; it is entirely dependent on the ecological interactions between the vector, the Ixodes tick, and the reservoir hosts. Understanding this enzootic cycle is fundamental to epidemiology.

The Vector: Ixodes scapularis

The primary vector in eastern North America is the blacklegged tick, Ixodes scapularis. Its life cycle spans two years and four distinct stages: egg, larva, nymph, and adult. The risk to humans is largely driven by the nymphal stage. Nymphs are diminutive (roughly the size of a poppy seed), making them difficult to detect, and their peak activity period in late spring and early summer coincides with human outdoor activity.¹⁸

Critically, B. burgdorferi is not transmitted transovarially (from mother tick to egg). Larval ticks hatch pathogen-free. They must acquire the bacteria by feeding on an infected reservoir host during their first blood meal. They then molt into nymphs, carrying the infection into the next year. This creates a critical bottleneck: the prevalence of disease depends entirely on the availability of competent reservoir hosts for the larvae.⁴

Reservoir Competence: The Keystone Role of the White-Footed Mouse

The concept of "reservoir competence" refers to the ability of a host species to maintain the pathogen and transmit it to a feeding tick. In the forests of the Northeast and Midwest, the white-footed mouse (Peromyscus leucopus) is the primary driver of infection.

• The White-Footed Mouse (Peromyscus leucopus): This species is a "super-spreader." It is highly competent, infecting between 40% and 90% of the larval ticks that feed on it.¹⁹ Crucially, the mouse is tolerant of the infection. Unlike other lab mice strains (e.g., C3H) that develop severe arthritis and carditis, P. leucopus maintains high bacterial burdens without significant tissue damage or behavioral illness. This tolerance ensures they remain active, foraging and collecting more ticks, effectively amplifying the pathogen in the environment.²⁰

• Secondary Reservoirs: Eastern chipmunks (Tamias striatus) and shrews (Blarina brevicauda) are moderately competent, contributing to the maintenance of the pathogen but at lower rates than mice.¹⁹

• Incompetent Hosts (Dead-Ends): The white-tailed deer (Odocoileus virginianus) plays a paradoxical role. It is the preferred host for the adult tick and is essential for tick reproduction (one deer can support hundreds of gravid female ticks). However, deer are biologically incompetent reservoirs. Their immune system kills B. burgdorferi, meaning a tick feeding on a deer will not become infected. Deer amplify the tick population but dilute the pathogen population.²²

The Dilution Effect: Complexity and Controversy

The interplay between these hosts led to the "Dilution Effect" hypothesis, which posits that high biodiversity reduces disease risk. The logic is that in a diverse ecosystem, many tick bites are "wasted" on incompetent hosts (like squirrels, raccoons, or deer) that fail to transmit the infection, thereby diluting the prevalence of infection in the tick population.²³ Conversely, in fragmented or disturbed habitats (like small suburban woodlots), biodiversity drops. The "weedy" species like white-footed mice thrive in these disturbed environments while predators and competitors vanish. This "monoculture" of competent hosts amplifies the disease risk.²⁴

However, recent meta-analyses from 2024 and 2025 have added nuance to this theory. Researchers argue that the Dilution Effect is not a universal law but a context-dependent phenomenon. Some studies suggest that adding species can sometimes have a null effect or even an amplification effect, depending on the specific competence of the species added. If the biodiversity added consists of moderately competent hosts (like chipmunks) that can "rescue" the pathogen when mouse numbers are low, the result might not be a simple reduction in risk.²⁵ Despite this debate, the consensus remains that habitat fragmentation is a major driver of risk, as it consistently favors the hyper-competent white-footed mouse.²⁴

IV. Molecular Pathogenesis: The Art of Evasion

Once a tick bites a human, Borrelia burgdorferi faces a formidable challenge: it must migrate from the tick's midgut to its salivary glands, enter the human skin, and survive the onslaught of the mammalian immune system. It achieves this through a sophisticated program of differential gene expression.

The OspA/OspC Switch

The bacterium's surface coat changes entirely during transmission, a process known as the OspA/OspC switch.

• In the Starving Tick: Within the midgut of an unfed tick, spirochetes express Outer Surface Protein A (OspA). OspA acts as a molecular anchor, binding to a tick receptor called TROSPA (Tick Receptor for OspA). This keeps the bacteria secure in the gut and protects them from antibodies ingested during previous blood meals.²⁷

• The Trigger: As the tick begins to feed, the influx of warm blood and nutrients triggers a regulatory cascade. The bacteria stop producing OspA (releasing the anchor) and begin producing Outer Surface Protein C (OspC).²⁷

OspC and Immune Evasion

OspC is the "invulnerability cloak" required for the initial stage of mammalian infection. Without OspC, the bacteria are instantly cleared by the host. Structural analysis reveals that OspC is a helical protein with a strong negative electrostatic potential, designed to interact with host ligands.³⁰

Its primary function is to disarm the complement system, the body's first line of defense. The complement system is a cascade of proteins that punches holes in bacterial membranes (the Membrane Attack Complex). Borrelia cannot survive this attack on its own.

• Mechanism: OspC binds to the host complement component C4b. By binding C4b, OspC inhibits the classical and lectin complement pathways. It essentially throws a wrench in the gears of the immune machine, preventing the formation of the membrane attack complex.³¹

• Factor H Recruitment: In addition to OspC, Borrelia produces proteins like CspZ that bind to Factor H, a host protein that naturally turns off the alternative complement pathway. By coating itself in Factor H, the bacterium masquerades as "self" tissue, tricking the immune system into standing down. Variations in CspZ sequences allow different Borrelia strains to bind Factor H from specific animals (e.g., rodents vs. birds), which dictates which animals the bacteria can infect (host tropism).³²

This molecular camouflage allows the spirochetes to survive in the bloodstream during the initial dissemination, travelling from the bite site to distal tissues like the joints, heart, and central nervous system.³³

V. Climate Change and Range Expansion

While biology dictates the potential of the spirochete, climate dictates its geography. Anthropogenic climate change is currently the most significant driver of Lyme disease expansion in North America.

Mechanisms of Expansion

Ticks are poikilotherms (cold-blooded); their metabolism, development, and survival are strictly regulated by temperature and humidity. Warming trends have unlocked vast new territories for Ixodes scapularis.

1. Winter Survival and the Thermal Death Line: Historically, the northern range of the blacklegged tick was limited by cold winters. Ticks overwinter in the leaf litter. While they can produce antifreeze proteins, prolonged exposure to extreme cold desiccates and kills them. However, winter minimum temperatures are rising faster than summer maximums. This retreat of extreme cold has allowed tick populations to survive further north each year.³⁴

2. Phenology and Degree Days: Ticks require a certain accumulation of heat (degree days) to molt from one stage to the next. Warmer springs and longer autumns increase the number of available degree days. This accelerates their life cycle, allowing populations to establish and reproduce more quickly. In some regions, this shift is causing tick activity to begin weeks earlier than historically recorded.⁵

3. Host Expansion: Climate change is also facilitating the northward expansion of the white-footed mouse and the white-tailed deer. As these hosts move north into the boreal forests of Canada, they carry the ticks—and the spirochetes—with them.³⁷

Geographic Projections (2025-2050)

Ecological niche modeling predicts a continued and rapid expansion of the risk map.

• Canada: The "front line" of Lyme disease is moving north. Models predict that by 2050, the suitable habitat for B. burgdorferi will expand northward by 250-500 km. The northern limit of the tick's range is expected to reach 50°N latitude by 2070. This puts major Canadian population centers, previously considered safe, squarely in the endemic zone.⁵

• The Westward Shift: In the United States, the disease is pushing west from the Northeast and Upper Midwest. States like Ohio, Illinois, and Iowa are seeing increasing establishment of tick populations in river valleys and forest fragments. High warming scenarios suggest that by mid-century, the burden of disease may shift significantly westward.³⁹

• Southern Contraction? Interestingly, some climate models suggest that extreme heat and drought in the southern United States may eventually make these regions less hospitable to Ixodes scapularis, which is highly sensitive to desiccation. This could lead to a future contraction of the range in parts of the South, even as it explodes in the North.³⁹

Table 2: Climate-Driven Range Dynamics of Lyme Disease Vectors

Region	Current Trend (2025)	Projected Status (2050)	Ecological Driver
Canada (Ontario/Quebec)	Rapid Emergence	Hyper-endemic	Warming winters; increased degree days allowing cycle completion.
Northeast US	Hyper-endemic	Saturation	Habitat saturation; maintenance of high reservoir density.
Appalachian Region	Altitude Expansion	High Elevation Spread	Ticks moving up mountain slopes (Blue Ridge) as altitudes warm.41
Mid-Atlantic (South)	Variable	Potential Decline	Extreme summer heat/drought exceeding tick physiological limits.
Midwest (OH, IL, IA)	Invasion	Establishment	Warmer winters allowing survival in fragmented woodlands.

VI. Contemporary Epidemiology and Surveillance (2024-2025)

Tracking Lyme disease is notoriously difficult due to the variability of symptoms and the limitations of diagnostic testing. The epidemiology of the mid-2020s is defined by a major shift in how cases are counted.

The 2022 Case Definition Change

In 2022, the Council of State and Territorial Epidemiologists (CSTE) and the CDC implemented a revised case definition. In "high-incidence" jurisdictions (16 states mostly in the Northeast and Midwest), cases can now be reported based on laboratory evidence alone. Previously, reporting required clinical information (like a doctor confirming an EM rash), which created a massive bottleneck; health departments simply didn't have the staff to call doctors for every positive lab result.⁴²

• The Statistical "Spike": This administrative change caused reported cases to jump by 69% in 2022, with over 62,000 cases reported. This does not represent a sudden biological outbreak, but rather a more accurate capture of the burden that was previously hidden by bureaucratic hurdles.⁴²

• True Burden: Despite these improvements, passive surveillance still misses many cases. The CDC maintains its estimate (based on insurance claims) that the true burden is approximately 476,000 diagnosed and treated cases per year in the United States.³

The Maryland Anomaly

While most regions show increases, some data from Maryland has shown a decrease or plateau in recent years. This has been a subject of investigation. Analyses suggest this is likely not a true biological decline but a result of "reporting fatigue" or specific changes in state-level surveillance practices. However, some climate models hint that Maryland, sitting on the southern edge of the high-incidence belt, might be seeing early impacts of the "southern contraction" due to rising temperatures, though this remains a hypothesis for future verification.³⁹

VII. Clinical Complexity: The PTLDS Consensus

For decades, patients with lingering symptoms after Lyme treatment faced skepticism from the medical establishment. The term "Chronic Lyme Disease" became a polarizing lightning rod. However, the release of the 2025 Consensus Study Report by the National Academies of Sciences, Engineering, and Medicine has fundamentally shifted the paradigm.

From Controversy to "Lyme IACI"

The report introduces the term Lyme Infection-Associated Chronic Illness (Lyme IACI) to describe the condition previously known as Post-Treatment Lyme Disease Syndrome (PTLDS). It acknowledges that 10-20% of patients treated for Lyme disease experience debilitating persistent symptoms, including severe fatigue, widespread musculoskeletal pain, cognitive dysfunction ("brain fog"), and sleep disturbances.⁹

Crucially, the report moves beyond the debate of existence to a focus on mechanism and treatment. It draws parallels with Long COVID (PASC) and ME/CFS, suggesting shared biological pathways of post-infectious illness.

Biological Mechanisms of PTLDS

Current research highlights three primary hypotheses for these persistent symptoms, which are likely overlapping:

1. Immune Dysregulation: The infection may trigger a "cytokine storm" or a persistent auto-inflammatory state that fails to resolve even after the bacteria are dead. Studies have identified elevated levels of inflammatory mediators like IL-6 and CXCL8 in the nervous tissues of affected models.⁴⁷

2. Antigenic Debris: While the bacteria may be killed by antibiotics, their "corpses"—fragments of peptidoglycan and DNA—can persist in tissues like the joints and cartilage. These remnants can continue to stimulate the immune system, causing chronic inflammation (a phenomenon known as "ghost" bacteria).⁴⁸

3. Neural Damage: The spirochete is neurotropic. During the acute phase, it can damage peripheral nerves or the central nervous system. Even if the infection is cleared, the neural injury may heal slowly or result in permanent neuropathic pain.⁴⁹

VIII. Therapeutic Frontiers: Beyond Doxycycline

The standard of care for acute Lyme disease—Doxycycline (100 mg twice daily for 10-14 days)—remains effective for the majority of early cases.⁵⁰ However, its broad-spectrum nature damages the gut microbiome, and it does not address the needs of PTLDS patients. The therapeutic landscape of 2025 is defined by the pursuit of specificity and host-directed therapies.

1. Hygromycin A: The Selective Assassin

Perhaps the most exciting development in antimicrobial therapy is the rediscovery of Hygromycin A. Originally discovered in the 1950s and discarded because it was ineffective against most bacteria, researchers at Northeastern University found that it is incredibly potent against spirochetes.

• Mechanism: Hygromycin A targets the ribosomal peptidyl transferase center of the bacterium. Because the spirochete ribosome has a slightly different shape than that of other bacteria or the host, the drug binds tightly to Borrelia but essentially bounces off other organisms.⁵¹

• Clinical Status: Flightpath Biosciences initiated Phase 1 human trials in 2024/2025. Preclinical studies in mice demonstrated that it could clear the infection effectively without disturbing the gut microbiome. If successful, this would be the first "Lyme-specific" antibiotic, offering a powerful tool for eradication without the collateral damage of dysbiosis.⁵¹

2. FGFR Inhibitors: Treating the Host, Not the Bug

Addressing the PTLDS population, researchers at Tulane University have identified Fibroblast Growth Factor Receptor (FGFR) inhibitors as a potential treatment for neuroinflammation.

• Rationale: Rather than trying to kill a bacterium that may no longer be there, this approach targets the host's inflammatory response. Borrelia infection upregulates FGFR signaling in the brain, leading to inflammation and neuronal cell death.

• Results: In primate tissue models, treating with FGFR inhibitors (drugs originally developed for cancer) significantly reduced the levels of inflammatory cytokines and stopped neuronal apoptosis. This offers a promising avenue for patients suffering from the "brain fog" and neuropathic pain of Lyme IACI.⁴⁹

3. VLA15: The Return of the Vaccine

After the withdrawal of the LYMErix vaccine in 2002, the field was dormant for two decades. That silence ended with the development of VLA15 by Valneva and Pfizer.

• Design: VLA15 is a multivalent recombinant protein vaccine. It targets the OspA protein of six different serotypes of Borrelia, covering the most common strains found in both North America and Europe.⁵⁴

• Mechanism of Action: The vaccine works on a principle of "transmission blocking." It generates antibodies in the human host. When a tick bites a vaccinated human, it ingests these antibodies. The antibodies travel to the tick's gut and neutralize the Borrelia bacteria inside the tick, preventing them from ever migrating to the human.¹⁶

• Status (2025): The pivotal Phase 3 "VALOR" trial completed its primary vaccination series in 2024. Data released in late 2025 demonstrated strong immunogenicity and a favorable safety profile, particularly after a booster dose. Pfizer aims to submit for FDA approval in 2026, creating a path for a public rollout by 2027.⁵⁴

Table 3: The Therapeutic Pipeline for Lyme Disease (2025)

Intervention	Type	Target	Status (2025)	Mechanism
VLA15 (Pfizer/Valneva)	Vaccine	Borrelia OspA	Phase 3 Completed	Neutralizes bacteria inside the tick gut.
Hygromycin A	Antibiotic	Ribosome	Phase 1 Trials	Selectively kills spirochetes; spares microbiome.
FGFR Inhibitors	Small Molecule	Host FGFR Pathway	Preclinical	Reduces neuroinflammation and neuronal death.
Doxycycline	Antibiotic	Ribosome (Broad)	Standard of Care	Broad-spectrum bacteriostatic (current gold standard).

IX. Conclusion

Lyme disease is a formidable adversary, forged by millions of years of evolution to persist in the wild and amplified by the ecological disruptions of the modern era. Its causative agent, Borrelia burgdorferi, possesses a genomic plasticity that allows it to evade the immune system and a stability that allows it to persist across continents.

The situation in 2025 is one of duality. On one hand, the ecological threat is growing. Climate change is fueling a relentless expansion of the tick vector into Canada and the West, exposing millions of naive hosts to the pathogen. On the other hand, the scientific response has never been more robust. The convergence of high-resolution genomics, the acknowledgment of chronic illness by major scientific bodies, and the arrival of novel, specific therapeutics and vaccines suggests that we are turning a corner.

We are moving from an era of passive observation and controversy to one of active intervention and mechanistic understanding. The goal for the next decade is clear: to deploy these new tools to break the transmission cycle, protect the vulnerable through vaccination, and restore health to those suffering from the long-term consequences of this ancient, expanding infection.

Data Sources & Citations:

• Epidemiology: ²

• Evolution/Genomics: ¹

• Ecology/Dilution Effect: ⁴

• Climate Change: ⁵

• Pathogenesis: ⁸

• Clinical/PTLDS: ⁹

• Treatments/Vaccines: ⁵⁰

Works cited

1. Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent Lyme disease emergence events | PNAS, accessed January 3, 2026, https://www.pnas.org/doi/10.1073/pnas.0903810106

2. Lyme Disease in the United States: Emerging Trends and Public Health Challenges, accessed January 3, 2026, https://globalhealth.euclid.int/lyme-disease-in-the-united-states-emerging-trends-and-public-health-challenges/

3. Lyme Disease Surveillance and Data - CDC, accessed January 3, 2026, https://www.cdc.gov/lyme/data-research/facts-stats/index.html

4. What is Driving the Global Expansion of Lyme Disease? - Contagion Live, accessed January 3, 2026, https://www.contagionlive.com/view/changes-in-latitude-changes-altitude-what-is-driving-the-global-expansion-of-lyme-disease-

5. Climate change and habitat fragmentation drive the occurrence of Borrelia burgdorferi, the agent of Lyme disease, at the northeastern limit of its distribution - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4227856/

6. Climate change is driving a rise in tick-borne diseases. Here's what to know. - CityNews Toronto, accessed January 3, 2026, https://toronto.citynews.ca/2025/06/28/climate-change-is-driving-a-rise-in-tick-borne-diseases-heres-what-to-know/

7. New study finds ticks carrying Lyme disease moving into western NC - UNCG Research, accessed January 3, 2026, https://research.uncg.edu/news/wasserberg-study-finds-ticks-carrying-lyme-disease-moving-into-western-nc/

8. A unique borrelial protein facilitates microbial immune evasion | mBio - ASM Journals, accessed January 3, 2026, https://journals.asm.org/doi/10.1128/mbio.02135-23

9. www.nationalacademies.org, accessed January 3, 2026, https://www.nationalacademies.org/read/28578/chapter/2

10. | Dated phylogeny of B. burgdorferi in North America. MCC tree of the... | Download Scientific Diagram - ResearchGate, accessed January 3, 2026, https://www.researchgate.net/figure/Dated-phylogeny-of-B-burgdorferi-in-North-America-MCC-tree-of-the-best-fitting-model_fig3_319323567

11. Genomic insights into the ancient spread of Lyme disease across North America - PMC, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6431794/

12. Lyme Disease Surveillance and Epidemiology in the United States: A Historical Perspective, accessed January 3, 2026, https://academic.oup.com/jid/article/230/Supplement_1/S11/7733440

13. Natural selection and recombination at host-interacting lipoprotein loci drive genome diversification of Lyme disease and related bacteria | mBio - ASM Journals, accessed January 3, 2026, https://journals.asm.org/doi/10.1128/mbio.01749-24

14. Evolutionary Genomics of Borrelia burgdorferi sensu lato: Findings, Hypotheses, and the Rise of Hybrids - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4299872/

15. Ancient Borrelia genomes document the evolutionary history of louse-borne relapsing fever, accessed January 3, 2026, https://www.biorxiv.org/content/10.1101/2024.07.18.603748v1.full-text

16. Outer-surface protein C of the Lyme disease spirochete: A protein induced in ticks for infection of mammals | PNAS, accessed January 3, 2026, https://www.pnas.org/doi/10.1073/pnas.0306845101

17. Ancient Borrelia genomes document the evolutionary history of louse-borne relapsing fever, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7617810/

18. Blacklegged Tick Surveillance - CDC, accessed January 3, 2026, https://www.cdc.gov/ticks/data-research/facts-stats/blacklegged-tick-surveillance.html

19. Lyme Disease [Research] - Cary Institute of Ecosystem Studies, accessed January 3, 2026, https://www.caryinstitute.org/science/research-projects/lyme-disease-research

20. Do white-footed mice, the main reservoir of the Lyme disease pathogen in the United States, clinically respond to the borrelial tenancy? - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11629617/

21. Comparative reservoir competence of Peromyscus leucopus, C57BL/6J, and C3H/HeN for Borrelia burgdorferi B31 - ASM Journals, accessed January 3, 2026, https://journals.asm.org/doi/10.1128/aem.00822-24

22. Estimating Reservoir Competence of Borrelia burgdorferi Hosts: Prevalence and Infectivity, Sensitivity, and Specificity - Oxford Academic, accessed January 3, 2026, https://academic.oup.com/jme/article/45/1/139/874411

23. The ecology of infectious disease: Effects of host diversity and community composition on Lyme disease risk - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC141036/

24. Biodiversity, Community Ecology, and the Dilution Effect, accessed January 3, 2026, https://www.caryinstitute.org/science/research-projects/biodiversity-community-ecology-and-dilution-effect

25. Reappraisal of the Dilution and Amplification Effect Framework: A Case Study in Lyme Disease | bioRxiv, accessed January 3, 2026, https://www.biorxiv.org/content/10.1101/2025.01.13.632839v1.full-text

26. Reappraisal of the Dilution and Amplification Effect Framework: A Case Study in Lyme Disease - PubMed, accessed January 3, 2026, https://pubmed.ncbi.nlm.nih.gov/40809833/

27. Reciprocal Expression of ospA and ospC in Single Cells of Borrelia burgdorferi - PMC - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2394987/

28. The Role of Borrelia burgdorferi Outer Surface Proteins - PMC - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3424381/

29. Functional Equivalence of OspA and OspB, but Not OspC, in Tick Colonization by Borrelia burgdorferi | Infection and Immunity - ASM Journals, accessed January 3, 2026, https://journals.asm.org/doi/10.1128/iai.00063-16

30. Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi - PMC - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC145497/

31. Borrelia burgdorferi outer surface protein C (OspC) binds complement component C4b and confers bloodstream survival - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5680108/

32. Structural evolution of an immune evasion determinant shapes pathogen host tropism | PNAS, accessed January 3, 2026, https://www.pnas.org/doi/10.1073/pnas.2301549120

33. Lyme Disease Pathogenesis - PMC - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8046170/

34. Effects of Climate Change on Ticks and Tick-Borne Diseases in Europe - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2648658/

35. Lyme disease is changing in a warming world — and so should the news, accessed January 3, 2026, https://healthjournalism.org/blog/2025/07/lyme-disease-is-changing-in-a-warming-world-and-so-should-the-news/

36. Possible Effects of Climate Change on Ixodid Ticks and the Pathogens They Transmit: Predictions and Observations - Oxford Academic, accessed January 3, 2026, https://academic.oup.com/jme/article/58/4/1536/5942051

37. How Climate Change is Affecting the Spread of Lyme Disease—and 5 Things You Need to Know About the Disease - Pfizer, accessed January 3, 2026, https://www.pfizer.com/news/articles/how_climate_change_is_affecting_the_spread_of_lyme_disease_and_5_things_you_need_to_know_about_the_disease

38. Rapid Northward Expansion of the Blacklegged Tick, Ixodes scapularis , in Response to Climate Change - PMC - PubMed Central, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12590538/

39. Could global warming cause a range expansion or shift of Lyme disease in the U.S. state of Maryland? A mathematical modeling approach | medRxiv, accessed January 3, 2026, https://www.medrxiv.org/content/10.1101/2025.08.31.25334788v1

40. Are you aware of the expanding reach of Lyme disease?, accessed January 3, 2026, https://www.hopkinslyme.org/lyme-disease-awareness/as-you-enjoy-the-springtime-are-you-aware-of-the-expanding-reach-of-lyme-disease/

41. Expanding range of Ixodes scapularis Say (Acari: Ixodidae) and Borrelia burgdorferi infection in North Carolina counties, 2018–2023 | PLOS One - Research journals, accessed January 3, 2026, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0329511

42. Surveillance for Lyme Disease After Implementation of a Revised Case Definition — United States, 2022 | MMWR - CDC, accessed January 3, 2026, https://www.cdc.gov/mmwr/volumes/73/wr/mm7306a1.htm

43. Tweak in surveillance leads to more reported Lyme disease cases in US - Healio, accessed January 3, 2026, https://www.healio.com/news/infectious-disease/20240221/tweak-in-surveillance-leads-to-more-reported-lyme-diseases-cases-in-us

44. Maryland Department of Health urges Marylanders to guard against tickborne diseases, accessed January 3, 2026, https://health.maryland.gov/newsroom/Pages/Maryland-Department-of-Health-urges-Marylanders-to-guard-against-tickborne-diseases.aspx

45. Mapping the distribution of Lyme disease at a mid-Atlantic site in the United States using electronic health data, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11142662/

46. Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses, accessed January 3, 2026, https://www.nationalacademies.org/read/28578/chapter/1

47. Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo - PMC, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11024320/

48. Post-Treatment Lyme Disease Syndrome May Be Driven by Remnants of Infection, accessed January 3, 2026, https://news.feinberg.northwestern.edu/2025/05/12/post-treatment-lyme-disease-syndrome-may-be-driven-by-remnants-of-infection/

49. New Treatment for Lyme Disease - Tulanian magazine - Tulane University, accessed January 3, 2026, https://tulanian.tulane.edu/summer-2024/new-treatment-lyme-disease

50. What are the most up to date guideline recommendations for the treatment of Lyme disease?, accessed January 3, 2026, https://dig.pharmacy.uic.edu/faqs/2025-2/july-2025-faqs/what-are-the-most-up-to-date-guideline-recommendations-for-the-treatment-of-lyme-disease/

51. Flightpath Biosciences Begins Human Clinical Testing of the World's First Narrow-Spectrum Antibiotic Targeting Lyme Disease, accessed January 3, 2026, https://flightpath.bio/flightpath-biosciences-begins-human-clinical-testing-of-the-worlds-first-narrow-spectrum-antibiotic-targeting-lyme-disease/

52. Evaluating the Ability of Hygromycin A to Reduce Lyme Disease Risk in Nature, accessed January 3, 2026, https://www.globallymealliance.org/news/evaluating-the-ability-of-hygromycin-a-to-reduce-lyme-disease-risk-in-nature

53. Study finds potential new treatment path for lasting Lyme disease symptoms, accessed January 3, 2026, https://tnbrc.tulane.edu/news/1652726/Study%20finds%20potential%20new%20treatment%20path%20for%20lasting%20Lyme%20disease%20symptoms

54. Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate, accessed January 3, 2026, https://valneva.com/wp-content/uploads/2025/09/2025_09_02_VLA15-221_m42_PR_EN_Final-1.pdf

55. Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate, accessed January 3, 2026, https://valneva.com/wp-content/uploads/2025/11/2025_11_26_VLA15_221_Phase-2_Results-1.pdf

56. Lyme Disease Facts and Statistics, accessed January 3, 2026, https://www.bayarealyme.org/about-lyme/lyme-disease-facts-statistics/

57. Changing Trends in Age and Sex Distributions of Lyme Disease—United States, 1992-2016, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9257499/

58. Tick, Tick: Spring Signals the Spread of Lyme Disease in the US | Contagion Live, accessed January 3, 2026, https://www.contagionlive.com/view/tick-tick-spring-signals-the-spread-of-lyme-disease-in-the-us

59. Accelerated phenology of blacklegged ticks under climate warming | Philosophical Transactions of the Royal Society B, accessed January 3, 2026, https://royalsocietypublishing.org/rstb/article/370/1665/20130556/42117/Accelerated-phenology-of-blacklegged-ticks-under

60. Proposed research classification criteria for Lyme disease in infection associated chronic illness studies - Frontiers, accessed January 3, 2026, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1519163/full